A Randomized, Double-Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effects of Tanezumab in Adult Patients With Chronic Low Back Pain.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2013
At a glance
- Drugs Tanezumab (Primary) ; Naproxen
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 22 Jul 2010 Planned end date changed from Jul 2010 to Aug 2010 as reported by ClinicalTrials.gov.
- 19 Jul 2010 Status changed from recruiting to suspended, based on a Pfizer media release. Adverse events were noted tanezumab recipients with osteoarthritis, and the FDA requested suspension based on the potential for adverse events in other patient populations.